Weekly Dynamics in Life Sciences and Healthcare (No.35): Key Developments from September 2–8, 2024

September 2,Shanghai Henlius Biotech, Inc.IND Application for HLX17, a Self-developed Biosimilar of Pembrolizumab, Approved by NMPA.

September 2,Hengrui PharmaTrastuzumab Deruxtecan for Injection, an ADC Targeting HER2, is Proposed by CDE for Priority Review.

September 2,GSK ChinaThe ADC injection belantamab mafodotin targeting BCMA is proposed by the CDE to be included in the priority review.

September 2,Skyline THERAPEUTICSSelf-developed adeno-associated virus gene therapy drug SKG1108 granted FDA orphan drug designation.

September 2nd and 3rd,Shanghai Institute of Materia MedicaResearch papers on the development of specific liver-targeting protein degraders and the elucidation of prolactin-releasing peptide receptor signaling mechanisms were published respectively inJournal of Controlled ReleaseAndCell Discovery。

September 3,InnoventListed on the STAR Market of the Shanghai Stock Exchange, achieving the first pharmaceutical IPO on the STAR Market this year.

September 3,Boehringer IngelheimAnnounced the acquisition of Saiba Animal Health AG.

September 4,EpimAb BiotherapeuticsAnnounced a strategic partnership with Vignette Bio for the development of the bispecific antibody EMB-06.

September 4,HuaotaThe Phase I clinical trial of ADCHB0052, a self-developed CD73 antigen-targeting drug, has completed the enrollment and dosing of its first subject.

September 5,AstraZenecaAnnounced a clinical research collaboration agreement with Hila Innovation.

Recently,InnoventCompleted tens of millions of yuan in Series A financing, led by Maotai Fund.

Recently,Obio Technology (Shanghai) Corp., Ltd.The first group standard in China, "Development Guidelines for (Cellular) Immunotherapy Products Based on mRNA-LNP Technology," deeply participated in editing, has been officially released.

Recently,EscugenCore Product ESG401's First-in-Human Phase Ia Clinical Trial Research Published inCell Reports Medicine。

Recently,MICURXCore product Contezolid Tablets successfully selected into the antibacterial drug clinical application grading management directories of multiple provinces and cities.

Recently,MedicilonStrategic cooperation reached with Shanghai GaoBo Oncology Hospital and Shida Pharmaceuticals.

Recently,SHANGHAI OUTDO BIOTECH CO.,LTD.Awarded the title of "Little Giant" enterprise specializing in new technologies at the national level.

Recently,Shanghai VasoLutions MedTech Co., Ltd.The peripheral vascular drug-eluting stent system successfully completed its first pre-market clinical implantation.

Recently,Shanghai Majorbio Bio-Pharm Technology Co., Ltd.Launch of Integrated Analysis Solution for Metaproteomics and Metagenomics.

Recently,YouDi BioCore Product UD-X™ Fully Automatic Single-Molecule Fluorescence Immunoassay Analyzer Approved for Marketing by Hebei Provincial Drug Administration.

Recently,Shanghai Fudan-Zhangjiang Bio-PharmaceuticalResults of Phase II Clinical Trial of Topical ALA Hydrochloride Powder Presented at the 53rd Annual Meeting of the European Society for Dermatological Research.

Recently,AkesoResults of Two Clinical Trials of Akeso's Globally First-in-Class PD-1/VEGF Bispecific Antibody Drug Evecanib Presented at the 25th World Conference on Lung Cancer.

Recently,Shanghai University of Traditional Chinese MedicineProfessor Xu Jianguo's team published a research paper in the field of precise mapping and modulation of cognitive neural circuits.Alzheimer’s & Dementia, et al. Liu Sanhong's research paper on the mechanism of norzelamal promoting anti-tumor immunity published inActa Pharmaceutica Sinica B。